Fagron's Share Buy-Back Program Completion
Fagron has recently concluded an important phase in its financial strategy with the successful completion of a share buy-back program. This initiative underscores the company's commitment to enhancing shareholder value and reinforcing its capital structure.
Details of the Buy-Back Program
Between 10 November 2025 and 14 November 2025, Fagron repurchased a total of 44,000 shares. The average price for these shares was €20.7208, resulting in an overall expenditure of approximately €911,717. In total, the company has repurchased 200,000 shares under this program, with an average price of €20.6805, leading to a cumulative investment of €4,136,093.
A Focus on Strategic Growth
This strategic move to buy back shares reflects Fagron's confidence in its long-term growth and its commitment to return value to shareholders. The shares acquired will be crucial for fulfilling obligations under Fagron’s incentive schemes, aligning the interests of employees and shareholders.
Background of the Program Announcement
The announcement of the buy-back program was made on 9 October 2025, highlighting Fagron's ongoing dedication to maintaining a robust balance sheet while actively pursuing avenues to boost shareholder confidence amidst a competitive market landscape.
Future Prospects for Fagron
As Fagron continues to evolve, it remains focused on its core mission of personalized medicine. The company strives to innovate and expand its offerings to hospitals, pharmacies, and clinics globally, thereby enhancing patient care and operational efficiency.
Upcoming Financial Calendar
Fagron has laid out a comprehensive financial calendar that outlines key upcoming events. Important dates to note include:
- Full year results 2025: 12 February 2026
- Trading update for first quarter 2026: 9 April 2026
- Annual General Meeting 2025: 11 May 2026
- Half year results 2026: 30 July 2026
- Trading update for third quarter 2026: 8 October 2026
Company Information
Fagron is a leader in pharmaceutical compounding, dedicated to providing personalized medicine across more than 35 countries. With its base in Nazareth, the company operates under the ticker symbol ‘FAGR’ on Euronext Brussels and Amsterdam.
Contact Details
For further inquiries or information, please contact:
Ignacio Artola
Global Investor Relations Leader
Ignacio.artola@fagron.com
Frequently Asked Questions
What is the purpose of the share buy-back program?
The goal of the share buy-back program is to enhance shareholder value and support the company's long-term incentive schemes.
How many shares did Fagron buy back?
Fagron repurchased a total of 200,000 shares during the buy-back program.
What was the average price of shares purchased?
The average price of shares purchased during the program was approximately €20.6805.
When was the buy-back program announced?
The buy-back program was announced on 9 October 2025.
What are Fagron's core business focuses?
Fagron primarily focuses on pharmaceutical compounding and delivering personalized medicine to improve patient care worldwide.